Gerrit L. J. Onderwater

Gerrit L. J. Onderwater

Auto-generated profile, based on publicly available information

Gerrit L. J. Onderwater

Department of Neurology Leiden University Medical Center Leiden The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2017 in Brain
Verified
Journal Article
Open access
PDF file
RZRonald Zielman
Ronald Zielman
JWJannie P. Wijnen
Jannie P. Wijnen
AWAndrew Webb
Andrew Webb
GOGerrit L. J. Onderwater
Gerrit L. J. Onderwater
IRItamar Ronen
Itamar Ronen
MKMark C. Kruit
Mark C. Kruit
Cortical hyperexcitability due to enhanced glutamatergic activity has been implicated in migraine pathophysiology but direct evidence is lacking. Here we assessed glutamate levels and intracellular mobility of glutamate in the visual cortex of migraineurs in-between attacks. We included 50 migraineurs (23 with aura and 27 without aura) and 24 age- and gender-matched non-headache controls. We used proton magnetic resonance spectroscopy (1H-MRS) and diffusion weighted spectroscopy at 7 T with a single volume of interest (2 × 2 × 3 cm) located in the primary and secondary visual cortex. For 1H-MRS we used a semi-LASER sequence with water referencing for absolute quantification. For diffusion weighted spectroscopy we used an adapted PRESS sequence with gradients applied in three directions and two different gradient amplitudes. Between-group differences were evaluated using analysis of covariance with the grey matter fraction in the volume of interest as covariate and post hoc comparisons with Bonferroni correction. Glutamate concentrations differed between groups (P = 0.047) and were higher in migraineurs without aura (mean ± standard deviation: 7.02 ± 0.50 mM) compared to controls (mean ± standard deviation: 6.40 ± 0.78 mM, P = 0.042). The apparent diffusion coefficient of glutamate was similar among groups (P = 0.129) suggesting similar inter- and intracellular mobility of glutamate in all three study groups. No differences were observed for concentrations and diffusion constants of other metabolites. The present study suggests that interictal glutamate levels are increased in the visual cortex of migraineurs without aura, supporting the hypothesis of cortical hyperexcitability in migraine.

16 April 2019 in Neurology
Verified
Journal Article
Open access
PDF file
GOGerrit L.J. Onderwater
Gerrit L.J. Onderwater
LLLannie Ligthart
Lannie Ligthart
MBMariska Bot
Mariska Bot
Ayse DemirkanAyse Demirkan
Ayse Demirkan
JFJing Fu
Jing Fu
OCon behalf of the BBMRI Metabolomics Consortium
on behalf of the BBMRI Metabolomics Consortium
Objective To identify a plasma metabolomic biomarker signature for migraine. Methods Plasma samples from 8 Dutch cohorts (n = 10,153: 2,800 migraine patients and 7,353 controls) were profiled on a 1H-NMR-based metabolomics platform, to quantify 146 individual metabolites (e.g., lipids, fatty acids, and lipoproteins) and 79 metabolite ratios. Metabolite measures associated with migraine were obtained after single-metabolite logistic regression combined with a random-effects meta-analysis performed in a nonstratified and sex-stratified manner. Next, a global test analysis was performed to identify sets of related metabolites associated with migraine. The Holm procedure was applied to control the family-wise error rate at 5% in single-metabolite and global test analyses. Results Decreases in the level of apolipoprotein A1 (β −0.10; 95% confidence interval [CI] −0.16, −0.05; adjusted p = 0.029) and free cholesterol to total lipid ratio present in small high-density lipoprotein subspecies (HDL) (β −0.10; 95% CI −0.15, −0.05; adjusted p = 0.029) were associated with migraine status. In addition, only in male participants, a decreased level of omega-3 fatty acids (β −0.24; 95% CI −0.36, −0.12; adjusted p = 0.033) was associated with migraine. Global test analysis further supported that HDL traits (but not other lipoproteins) were associated with migraine status. Conclusions Metabolic profiling of plasma yielded alterations in HDL metabolism in migraine patients and decreased omega-3 fatty acids only in male migraineurs.

23 July 2019 in Neurology
Verified
Journal Article
Open access
PDF file
RDRobin M. van Dongen
Robin M. van Dongen
LWLindy C. Waaijer
Lindy C. Waaijer
GOGerrit L.J. Onderwater
Gerrit L.J. Onderwater
MFMichel D. Ferrari
Michel D. Ferrari
GTGisela M. Terwindt
Gisela M. Terwindt
Objective To evaluate pharmacologic treatment options for visual snow and to report prevalence of comorbid diseases. Methods Medical charts of patients with a diagnosis of visual snow at the neurology outpatient clinic were reviewed on prescribed medication, and comorbid migraine, tinnitus, and psychiatric conditions including depression and anxiety. Results From 2007 to 2018, 58 patients were diagnosed with visual snow. Comorbid migraine was present in 51.7% of patients, lifetime depression in 41.4%, and lifetime anxiety in 44.8%. Lamotrigine was prescribed most frequently (26/58) and resulted in partial remission of symptoms in 5/26 (19.2%). No patients reported complete remission. Adverse events occurred in 13/26 (50.0%) patients. None of the other prescribed drugs (valproate [n = 7], topiramate [n = 4], acetazolamide [n = 2], flunarizine [n = 1]) led to improvement except for topiramate in one patient, who discontinued, however, because of adverse events. Conclusions Of medication prescribed (lamotrigine, valproate, acetazolamide, flunarizine), only lamotrigine afforded some improvement in a small minority of patients. Migraine, depression, anxiety, and tinnitus were common comorbid diseases. Classification of evidence This study provides Class IV evidence that for some patients with visual snow, lamotrigine resulted in partial remission of symptoms.

18 December 2018 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GOG. L. J. Onderwater
G. L. J. Onderwater
WOW. P. J. van Oosterhout
W. P. J. van Oosterhout
GSG. G. Schoonman
G. G. Schoonman
MFM. D. Ferrari
M. D. Ferrari
GTGisela M. Terwindt
Gisela M. Terwindt

1 March 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
VKVasudev Kantae
Vasudev Kantae
SOShinji Ogino
Shinji Ogino
MNMarek Noga
Marek Noga
AHAmy C. Harms
Amy C. Harms
RDRobin M. van Dongen
Robin M. van Dongen
THThomas Hankemeier
Thomas Hankemeier
Endocannabinoids, a class of lipid messengers, have emerged as crucial regulators of synaptic communication in the central nervous system (CNS). Dysregulation of these compounds has been implicated in many brain disorders. Although some studies have identified and quantified a limited number of target compounds, a method that provides comprehensive quantitative information on endocannabinoids and related N-acylethanolamines (NAEs) in CSF is currently lacking as measurements are challenging due to low concentrations under normal physiological conditions. Here we developed and validated a high-throughput nano liquid chromatography-electrospray ionization mass spectrometry (nano LC-ESI-MS/MS) platform for the simultaneous quantification of endocannabinoids (anandamide (AEA), 2-arachidonoyl glycerol (2-AG)), ten related NAEs and eight additional putatively annotated NAEs in human CSF. Requiring only 200 μL of CSF our method has limits of detection from 0.28 to 61.2 pM with precisions of RSD <15% for most compounds. We applied our method to CSF from 45 healthy humans and demonstrated potential age and gender effects on concentrations of endocannabinoids and NAEs. Notably, our results show that docosahexaenoyl ethanolamide (DHEA) concentrations increase with age in males. Our method may offer new opportunities to gain insight into regulatory functions of endocannabinoids in the context of (ab)normal brain function.

12 May 2021 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
RDRobin M. van Dongen
Robin M. van Dongen
GAGerard J. Alderliefste
Gerard J. Alderliefste
GOGerrit L. J. Onderwater
Gerrit L. J. Onderwater
MFMichel D. Ferrari
Michel D. Ferrari
GTGisela M. Terwindt
Gisela M. Terwindt
Background and purpose: This study was undertaken to investigate migraine prevalence in persons with hallucinogen persisting perception disorder (HPPD) presenting as visual snow syndrome (VSS).Methods: Persons with visual snow as a persisting symptom after illicit drug use (HPPD) were recruited via a Dutch consulting clinic for recreational drug use. A structured interview on (visual) perceptual symptomatology, details of drugs use, and medical and headache history was taken. As a control group, persons with visual snow who had never used illicit drugs prior to onset were included. The primary outcome was lifetime prevalence of migraine. Symptom severity was evaluated by the Visual Snow Handicap Inventory (VHI), a 25‐item questionnaire.Results: None of the 24 HPPD participants had migraine, whereas 20 of 37 (54.1%) controls had migraine (p < 0.001). VHI scores did not differ significantly between the two groups; in both groups, the median score was 38 of 100. In most HPPD cases (17/24, 70.9%), visual snow had started after intake of ecstasy; other psychedelic drugs reported included cannabis, psilocybin mushrooms, amphetamine, 4‐fluoroamphetamine, 3‐methylmethcathinone, 4‐Bromo‐2,5‐dimethoxypenethylamine, and nitrous oxide.Conclusions: Whereas none of the HPPD participants had migraine, more than half of the visual snow controls without prior use of illicit drugs had migraine. This suggests that at least partly different pathophysiological factors play a role in these disorders. Users of ecstasy and other hallucinogens should be warned of the risk of visual snow. Further studies are needed to enhance understanding of the underlying neurobiology of HPPD and VSS to enable better management of these conditions.